Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deal Watch: Best Value For Smaller Firms Lies In The Back-End

Executive Summary

With more deals on earlier-stage platform technologies and compounds, the companies offering such assets need to take a rational approach to pricing – accepting a lot of potential back-end compensation – to get fair value, one analyst says.

You may also be interested in...



Start-Up Quarterly Statistics: Early Funding Declined, But Deal Dollars Flowed

A review of biopharma startup dealmaking and financing activity from January through March 2017, based on data from Strategic Transactions, showed a 19% decline in startup financing compared with the fourth quarter of 2016, but big pharmas provided capital in the form of alliance fees.

Takeda Adds Exelixis Arrow To Oncology Quiver

Takeda's acquisition of Japanese rights to Exelixis' lead product fills a gap in the oncology portfolio while adding another piece to the US company's global licensing jigsaw.

Incyte Further Enhances IO Pipeline With Calithera's Arginase Inhibitor

In its second cancer deal in two months, Incyte licenses a first-in-class asset expected to offer potential cancer immunotherapy synergy with IDO1 and checkpoint inhibition.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

ID1131516

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel